Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-04
2006-07-04
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S647000, C514S649000, C514S657000
Reexamination Certificate
active
07071194
ABSTRACT:
The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.
REFERENCES:
patent: 5530029 (1996-06-01), Maltin
patent: 5541188 (1996-07-01), Maltin
patent: 5552442 (1996-09-01), Maltin
patent: 5885976 (1999-03-01), Sandyk
patent: WO 01/68073 (2001-09-01), None
Garner et al, 110CA:185838, 1989.
Lalley et al, 121CA: 1611, 1994.
Van Der Heijden, 129CA:254758, 1998.
Merck Manual of Medical Information, Berkow et al Eds, Pocket Books, New York, 1997, pp. 361-362.
Teng et al. Treatment with 5HT1A receptor agonists reverses respiratory abnormalities spinal cord injured rats, Society for Neuroscience Abstracts, 1999, vol. 25, No. 1-2, p. 1333. Meeting held on Oct. 23-28, 1999.
Agbenya, E.T., et al., “Effect of Clenbuterol on Normal and Denervated Muscle Growth and Contractility,”Muscle and Nerve, 13:199-203 (1990).
Bardsley, R.G., et al., “Effect of β-agonists on Expression of Calpain and Calpastatin Activity in Skeletal Muscle, ”Biochmic, 267-273 (1992).
Brown, R.H., Jr., “Amyotrphic Lateral Schlerosis,”Arch. Neurol., 54:1246-1250 (1997).
Chancellor, A.M., et al., “Adult onset Motor Neuron Disease: Worldwide Mortality, Incidence and Distribution Since 1950,”Journal of Neurology, Neurosurgery and Psychiatry, 55:1106-1115 (1992).
Culmsee, C., et al., “Clenbuterol Induces Growth Factor mRNA, Activates Astrocytes, and Protects Rat Brain Tissue Against Ischemic Damage,”European Journal of Pharmacology, 379:33-45 (1999).
Culmsee, C., et al., “NGF Mediates the Neuroprotective Effect of the β2-adrenoceptor Agonist Clenbuterol In Vitro and In Vivo: Evidence from an NGF-Antisense Study,”Neurochemistry International, 35:47-57(1999).
Kahn, T., et al., “Muscle Atrophy Reversed by Clenbuterol Following Chronic Spinal Cord Injury,”Regeneration R&D Service, 88:15 p. 218. 1999.
Maltin, C.A., et al. “Clenbuterol, a β-aderenoceptor Agonist, Increases Relative Muscle Strength in Orthopaedic Patients,”Clinical Science, 84:651-654 (1993).
Martineau, L., et al., “Salbutamol, a β2-adrenoceptor Agonist, Increases Skeletal Muscle Strength in Young Men,”Clinical Science, 83:615-621 (1992).
D.M. Rapoport, et al., “Comparison of the Effects of Busiprone and Diazepam on Control of Breathing,”Control of Breathing: Integrated(7028-7033).
Sahibzada, N., et al., “Reversal of Morphine-Induced Apnea in the Anesthetized Rat by Drugs that Activate 5-Hydroxytryptamine1AReceptors,”The Journal of Pharmacology and Experimental Therapeutics, 292:704-713 (2000).
Zeman, R.J., “Clenbuterol, a β2-agonist, Retards Wasting and Loss of Contractility in Irradiated DystropicmdxMuscle,”The American Physiological Society, 865-868 (1994).
Zeman, R.J., et al., “Clenbuterol, a β2-agonist, Retards Atrophy in Denervated Muscles,”The American Physiological Society, 152-155 (1987).
Zeman, R.J., et al., “Slow to Fast Alterations in Skeletal Muscle Fibers Caused by Clenbuterol, a β2Receptor Agonist,”The American Physiological Society, 726-732(1988).
Lalley, P.M., et al., “Serotonin 1A-Receptor Activation Suppresses Respiratory Apneusis in the Cat,”Neurosci. Lett., 172:59-62 (1994).
Berkow, R., et al., “Disorders of Muscle Stimulation,” The Merck Manual of Medical Information, (Pocket Books) pp. 331-332 (1997).
Garner, S.J., et al., “Buspirone, and Anxiolytic Drug that Stimulates Respiration,”Am. Rev. of Respir. Dis.139:946-950 (1989).
Van Der Heijden, H.F.M., et al., “Long-term Effects of Clenbuterol on Diaphragm Morphology and Contractile Properties in Emphysematous Hamsters,”J. of Appl. Physiol.85(1):215-222 (1998).
Teng, Y.D., et al., “Treatment with 5HT1A Receptor Agonists Ameliorates Respiratory Abnormalities in SOD1 Mice,”Society For Neuroscience, 31stAnnual Meeting, San Diego, Calif. Nov. 10-15, 2001, Abstract 106.9.
Maltin, C.A., et al., “Clenbuterol, a β-adrenoceptor Agonist, Increases Relative Muscle Strength in Orthopaedic Patients,”Clin Sci., 84:651-654 (1993).
Miller, RG, et al., Riluzole for Amyothrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) (Review),The Cochrane Database of Systematic Reviews, 2: 1-23 (Art. No. CD001447) (2002).
Hamilton Brook Smith & Reynolds P.C.
The Children's Medical Center Corporation
Wang Shengjun
LandOfFree
Method for improving respiratory function and inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for improving respiratory function and inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for improving respiratory function and inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3592250